Rethinking the CAR-T Manufacturing Workflow

Autologous CAR-T therapy has transformed outcomes in hematologic malignancies, but its broader clinical impact remains constrained by manufacturing processes that are complex, time-intensive, and costly. Conventional workflows require multiple discrete steps — T cell enrichment, activation, and transduction — each adding materials, labor, and variability that drive up per-dose cost and limit scalability.

MadeFast™ is Made Scientific's single-step CAR-T manufacturing framework, designed to consolidate enrichment, activation, and transduction into a single operation early in the process — with the potential to eliminate CD4/CD8 pre-enrichment entirely.

Download the white paper to see how MadeFast performed in its first proof-of-concept study, with Syenex's RapidCell™ Lentiviral Vector for T cells as the enabling technology.

What's Inside:

• Up to 97% CAR transduction in unfractionated PBMCs without CD4/CD8 enrichment
• Estimated ≥50% per-dose COGS reduction vs. conventional workflows
• Full proof-of-concept data on cytotoxicity, IFN-γ secretion, and cell quality